These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 25724578)
1. CD133 marks a stem cell population that drives human primary myelofibrosis. Triviai I; Stübig T; Niebuhr B; Hussein K; Tsiftsoglou A; Fehse B; Stocking C; Kröger N Haematologica; 2015 Jun; 100(6):768-79. PubMed ID: 25724578 [TBL] [Abstract][Full Text] [Related]
2. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. Massa M; Rosti V; Ramajoli I; Campanelli R; Pecci A; Viarengo G; Meli V; Marchetti M; Hoffman R; Barosi G J Clin Oncol; 2005 Aug; 23(24):5688-95. PubMed ID: 16110028 [TBL] [Abstract][Full Text] [Related]
3. Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging. Isidori A; Motta MR; Tani M; Terragna C; Zinzani P; Curti A; Rizzi S; Taioli S; Giudice V; D'Addio A; Gugliotta G; Conte R; Baccarani M; Lemoli RM Biol Blood Marrow Transplant; 2007 Oct; 13(10):1224-32. PubMed ID: 17889360 [TBL] [Abstract][Full Text] [Related]
4. Characterization of serum-free ex vivo-expanded hematopoietic stem cells derived from human umbilical cord blood CD133(+) cells. Yao CL; Feng YH; Lin XZ; Chu IM; Hsieh TB; Hwang SM Stem Cells Dev; 2006 Feb; 15(1):70-8. PubMed ID: 16522164 [TBL] [Abstract][Full Text] [Related]
5. Proliferation and differentiation potential of CD133+ and CD34+ populations from the bone marrow and mobilized peripheral blood. Koutna I; Peterkova M; Simara P; Stejskal S; Tesarova L; Kozubek M Ann Hematol; 2011 Feb; 90(2):127-37. PubMed ID: 20821012 [TBL] [Abstract][Full Text] [Related]
6. CD133 allows elaborated discrimination and quantification of haematopoietic progenitor subsets in human haematopoietic stem cell transplants. Radtke S; Görgens A; Kordelas L; Schmidt M; Kimmig KR; Köninger A; Horn PA; Giebel B Br J Haematol; 2015 Jun; 169(6):868-78. PubMed ID: 25819405 [TBL] [Abstract][Full Text] [Related]
7. Large-scale isolation of CD133+ progenitor cells from G-CSF mobilized peripheral blood stem cells. Gordon PR; Leimig T; Babarin-Dorner A; Houston J; Holladay M; Mueller I; Geiger T; Handgretinger R Bone Marrow Transplant; 2003 Jan; 31(1):17-22. PubMed ID: 12621502 [TBL] [Abstract][Full Text] [Related]
8. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936 [TBL] [Abstract][Full Text] [Related]
9. ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF. Triviai I; Zeschke S; Rentel J; Spanakis M; Scherer T; Gabdoulline R; Panagiota V; Thol F; Heuser M; Stocking C; Kröger N Leukemia; 2019 Jan; 33(1):99-109. PubMed ID: 29907810 [TBL] [Abstract][Full Text] [Related]